Home › Familial Amyloid Neuropathies › NCT07583823
Elevated Rate Pacing of Cardiac Amyloidosis
Recruiting
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Adults 18 and older * Diagnosis of cardiac amyloidosis as indicated by the criteria set forth in guidelines such as in Kittleson et al: "2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee * Implanted Cardiac Pacemaker (+/- Defibrillator) * Pacemaker mode of AAI or DDD if in sinus rhythm, VVI acceptable if permanent atrial fibrillation * Non-dilated left ventricle by echocardiography * Ability to provide written consent * English Speaking Exclusion Criteria: * Paced QRS duration of \>150 ms (indicator for pacing mediated dyssynchrony) * Dilated left ventricle
About the study
This study aims to better quantify the improvements in heart failure symptoms and exercise tolerance before and after the heart rate elevation in a cohort of 10 cardiac amyloidosis patients with preexisting pacemakers.
What is being tested
- Pacemaker Rate (other)
Sponsor: University of Minnesota · Participants: 10 · Started: Oct 10, 2025
Contact the study team
- Meghan Muscala · Phone: 612-626-5863
Official record on ClinicalTrials.gov — NCT07583823
Locations in the U.S.
| Minnesota | University of Minnesota, Minneapolis |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.